Scientists discover major cause of inflammatory bowel disease

Scientists discover major cause of inflammatory bowel disease

A team of scientists in the United Kingdom have discovered a major cause of inflammatory bowel disease (IBD) which affects millions of people across the globe. According to a report by the BBC, scientists found a weak spot in human DNA that is present in 95 per cent of people with the disease, making it …

Read more

ChatGPT May Be Useful, Reliable Tool for Healthcare Professionals in IBD, Study Finds

ChatGPT May Be Useful, Reliable Tool for Healthcare Professionals in IBD, Study Finds

Credit: Matheus Bertelli on Pexels ChatGPT may be a useful and reliable resource for healthcare professionals in the context of inflammatory bowel disease (IBD), according to findings from a recent study. When asked a set of 20 questions patient- and healthcare professional-oriented questions about ulcerative colitis (UC) and Crohn disease (CD), the large language model …

Read more

From immune modulators to microRNA therapies

From immune modulators to microRNA therapies

Inflammatory bowel disease (IBD) refers to a spectrum of chronic bowel inflammatory conditions, primarily ulcerative colitis (UC) and Crohn’s disease (CD). These autoimmune mucosa-damaging conditions cause pain, bloating, indigestion, and acute abdominal emergencies, severely reducing the quality of life in the long term. Newer therapies have emerged based on a better understanding of the pathophysiology …

Read more

Genesis Therapeutics Rakes In $200M For AI-Powered Drug Discovery

Genesis Therapeutics Rakes In 0M For AI-Powered Drug Discovery

Several startups focused on AI-powered drug discovery have closed multi-million-dollar funding rounds this year, including Causaly, BenchSci, Iktos, TandemAI and Protai. Another one joined the list on Monday.  Genesis Therapeutics announced the close of a $200 million Series B funding round, taking the Burlingame, California-based company’s total funding to date to more than $280 million. …

Read more